GREGORY L. WEAVER - 26 Feb 2026 Form 4 Insider Report for Altimmune, Inc. (ALT)

Role
Chief Financial Officer
Signature
/s/ Gregory Weaver, as Attorney-in-Fact
Issuer symbol
ALT
Transactions as of
26 Feb 2026
Net transactions value
$0
Form type
4
Filing time
27 Feb 2026, 16:05:36 UTC
Previous filing
12 Nov 2025
Next filing
09 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
WEAVER GREGORY L Chief Financial Officer 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG /s/ Gregory Weaver, as Attorney-in-Fact 27 Feb 2026 0001251779

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALT Stock Options (option to buy) Award $0 +259,000 $0.000000 259,000 26 Feb 2026 Common Stock, par value $0.0001 259,000 $4.46 Direct F1
transaction ALT Restricted Stock Units Award $0 +111,000 $0.000000 111,000 26 Feb 2026 Common Stock, par value $0.0001 111,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the option become vested and exercisable over four (4) years with 25% of the shares vesting on February 26, 2027, with the remainder vesting in equal monthly installments for the following thirty-six (36) months, subject to the reporting person's continued service on each applicable vesting date.
F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
F3 The RSUs become vested over four (4) years with 25% of the shares vesting February 26, 2027, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.